GCPII inhibitors comprising 2-(phosphonomethyl) pentanedioic acid (2-PMPA) conjugated to a bile acid and their use for treating a disease or condition associated with elevated levels of GCPII, including inflammatory bowel disease.

The present disclosure is directed to formulations comprising (1) at least one formulation transport agent, (2) at least one complexing agent, and (3) at least one active agent that modulates one or more traits of a target insect, plant, or plant pathogen. The present disclosure is also directed to methods of delivering such formulations to the target organism, as well as to formulation transport agents used to prepare such formulations.

Amphiphilic compounds with tetradecahydrophenanthrene skeleton and their enantiomers, exhibiting neuroprotective effects, their use in methods of treatment of neuropsychiatric disorders associated with an imbalance in glutamatergic neurotransmitter system, such as ischemic damage of CNS, neurodegenerative changes and disorders of CNS, affective disorders, depression, post-traumatic stress disorder and diseases related to stress, anxiety, schizophrenia and psychotic disorders, pain, addiction, multiple sclerosis, epilepsy, glioma, and a pharmaceutical composition containing compound.

The present disclosure relates to compositions derived from bioreachable molecules, such as amino acids and/or steroids. In particular, the composition can be a monomer, a polymer, or a copolymer derived from an amino acid dimer. Such compositions can optionally include a functionalized steroid.

Provided are panaxdiol-type ginsenoside derivatives having structures as shown in formula I or formula II. Also provided are the uses thereof in the preparation of drugs for preventing and treating atherosclerosis. The panaxdiol-type ginsenoside derivatives have low cytotoxicities, can significantly reduce the percentages of the areas of atherosclerotic plaques in apoE−/− mice, can also effectively reduce the levels of low-density lipoprotein cholesterol and increase the levels of high-density lipoprotein cholesterol in serums of mice, and can significantly reduce the local TNF-α levels in the arteries of apoE−/− mice and have good anti-inflammatory effects; at a dose of 30 μM, the panaxdiol-type ginsenoside derivatives can significantly reduce the degrees of the formation of RAW264.7 cell-derived foam cells. In addition, the preparation methods for the panaxdiol-type ginsenoside derivatives are easy to operate and obtain high yields.

The clarity method for biotissue using a biotissue clearing agent including CHAPS of the present invention enables fast tissue clarity without denaturation.

The invention relates to compounds of formula (I), their method of synthesis as well as their use to treat neurodegenerative disorders.

The Invention provides a novel delivery system for delivery of drugs across biological membranes. It provides novel chemical conjugates that comprise said delivery system, methods for synthesis of said compounds, and methods for utilization of said delivery system, among others, for delivery of genetic drugs into tissues and cells, in vitro, ex vivo, and in vivo, for the treatment of various medical disorders.

The clarity method for biotissue using a biotissue clearing agent including CHAPS of the present invention enables fast tissue clarity without denaturation.

Provided are panaxdiol-type ginsenoside derivatives having structures as shown in formula I or formula II. Also provided are the uses thereof in the preparation of drugs for preventing and treating atherosclerosis. The panaxdiol-type ginsenoside derivatives have low cytotoxicities, can significantly reduce the percentages of the areas of atherosclerotic plaques in apoE/mice, can also effectively reduce the levels of low-density lipoprotein cholesterol and increase the levels of high-density lipoprotein cholesterol in serums of mice, and can significantly reduce the local TNF- levels in the arteries of apoE/mice and have good anti-inflammatory effects; at a dose of 30 M, the panaxdiol-type ginsenoside derivatives can significantly reduce the degrees of the formation of RAW264.7 cell-derived foam cells. In addition, the preparation methods for the panaxdiol-type ginsenoside derivatives are easy to operate and obtain high yields.